59 episodes

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast PeerView Press

    • Science
    • 4.2 • 9 Ratings

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    Donna H. Ryan, MD, FTOS -Demystifying the Role of Incretin-Based Weight-Loss Pharmacotherapy: A Patient-Centered Approach to Overcoming Barriers and Addressing Underlying Causes of Obesity

    Donna H. Ryan, MD, FTOS -Demystifying the Role of Incretin-Based Weight-Loss Pharmacotherapy: A Patient-Centered Approach to Overcoming Barriers and Addressing Underlying Causes of Obesity

    Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.

    • 24 min
    Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

    Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

    Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.

    • 1 hr
    R. Robert Auger, MD, FAASM, FAPA, DABPN - The Dawn of a New Era: Recent Advances in the Pharmacologic Management of Idiopathic Hypersomnia

    R. Robert Auger, MD, FAASM, FAPA, DABPN - The Dawn of a New Era: Recent Advances in the Pharmacologic Management of Idiopathic Hypersomnia

    Go online to PeerView.com/ETX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in sleep medicine discusses recent guidelines and evidence presented at the SLEEP 2021, a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, on the pharmacologic management of idiopathic hypersomnia (IH). Upon completion of this accredited CE activity, participants should be better able to: Employ currently recommended approaches and available assessment tools to identify and differentially diagnose patients with IH, Incorporate the latest guideline recommendations and evidence for approved and emerging pharmacotherapies to optimize the management of patients with IH, Evaluate the clinical potential of recent advances in the pharmacologic treatment of patients with IH.

    • 36 min
    Loren D.M. Pena, MD, PhD - Advancing the Treatment of Pompe Disease: Clinical Updates in Newborn Screening and Enzyme Replacement

    Loren D.M. Pena, MD, PhD - Advancing the Treatment of Pompe Disease: Clinical Updates in Newborn Screening and Enzyme Replacement

    Go online to PeerView.com/AFD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Pompe disease discusses the presentation of infantile- and late-onset Pompe disease, as well as treatment via enzyme replacement therapy. Upon completion of this accredited CE activity, participants should be better able to: Employ recommended assessments, including newborn screening (NBS), clinical presentation, and appropriate tests, to diagnose Pompe disease in a timely manner, Apply current recommendations and evidence regarding use of enzyme replacement therapy in the interdisciplinary management of Pompe disease, Recognize the potential role of emerging enzyme-replacement therapies in the treatment of Pompe disease.

    • 23 min
    Stuart H. Isaacson, MD - Managing Motor Complications in Parkinson’s Disease: Evaluating the Role of On-Demand Therapies for “Off” Episodes

    Stuart H. Isaacson, MD - Managing Motor Complications in Parkinson’s Disease: Evaluating the Role of On-Demand Therapies for “Off” Episodes

    Go online to PeerView.com/BPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the management of motor complications in Parkinson’s disease. Upon completion of this accredited CE activity, participants should be better able to: Identify the need to adjust treatment for “off” episodes in Parkinson’s disease through symptom and therapy assessment and clear communication with patients and/or caregivers, Interpret evidence regarding on-demand treatment options and their role in the management of “off” episodes in Parkinson’s disease, Apply on-demand treatment options, based on current evidence, in the personalized management of “off” episodes in Parkinson’s disease.

    • 30 min
    Jinsy A. Andrews, MD, MSc, FAAN - A Visual Exploration of Antisense Oligonucleotide Therapies in Amyotrophic Lateral Sclerosis

    Jinsy A. Andrews, MD, MSc, FAAN - A Visual Exploration of Antisense Oligonucleotide Therapies in Amyotrophic Lateral Sclerosis

    Go online to PeerView.com/DYM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the use of antisense oligonucleotide therapies in patients with amyotrophic lateral sclerosis (ALS). Upon completion of this accredited CE activity, participants should be better able to: Identify common genes and cellular processes implicated in ALS pathogenesis, Recognize the mechanisms of action, efficacy, and safety profiles of emerging ALS therapies including antisense oligonucleotides, Discuss how the ALS treatment paradigm may change as a result of emerging therapies, Educate patients with ALS about ongoing clinical trials evaluating novel disease-modifying therapies.

    • 25 min

Customer Reviews

4.2 out of 5
9 Ratings

9 Ratings

Top Podcasts In Science

You Might Also Like

More by PeerView Press